Ret Recombinant Rabbit mAb (S-5298)

RET is a single-pass transmembrane protein encoded by the RET proto-oncogene, playing a central role in embryonic development, cell survival, differentiation, and proliferation. Its activation depends on ligand-induced dimerization (with ligands such as GDNF family ligands binding to the co-receptor GFRα), which subsequently triggers phosphorylation cascades within the intracellular tyrosine kinase domain, activating multiple downstream signaling pathways including RAS-MAPK and PI3K-AKT. Functionally, RET is essential for kidney development, the formation of the enteric nervous system, and sympathetic neuron survival, and loss-of-function mutations in the gene lead to Hirschsprung's disease. Pathologically, gain-of-function point mutations and gene rearrangements of RET are key drivers of various tumors, most notably medullary thyroid carcinoma (where RET mutations are present in nearly all hereditary cases and a subset of sporadic cases) and papillary thyroid carcinoma (where RET gene rearrangements frequently generate fusion proteins). In recent years, RET-targeted inhibitors (such as Selpercatinib and Pralsetinib) have demonstrated significant therapeutic efficacy in treating these RET-driven tumors.